Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Remdesiver failed it first trial but went on to be standard of care in the US so in this light you can't just disregard B for not meeting it's primary endpoint in this moderate to severe trial alone, the science community clearly hasn't. B is still being studied as a broad-spectrum anti-viral (now over 20 viruses) and as a anti-fungal with reported success in both. From scientific papers we know a nasally form of B is in the works to address the virus early while it's still replicating in the airways.

June 23
"While the trial did not meet its primary endpoint in reducing time to sustained recovery through day 29, certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03). To date, only a modicum of success has been demonstrated by any company conducting clinical trials in moderate-to-severe hospitalized cases of COVID-19. A possible reason for this may be owing to frequent changes in the standard of care with patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin further lead us to believe that higher and more frequent dosing of Brilacidin may be more appropriate to tackle this complex disease in the hospital setting".